Foxa1 decreases FA uptake. by Marta Moya (188959)

MVK activates microglia and decreases phagocytosis. by Ren Y. Sato (16914027)

Neuroapoptosis decreases following CO exposure. by Ying Cheng (288456)

LMP1 decreases mitochondrial respiration. by Michael Hulse (5932112)

Decrease of receptor detectibility following CRAD replication in a small fraction of cells. by Johan Rebetz (255622)

Stat1 activation is strongly decreased by MNV-S99 infection. by Sandra Niendorf (2832785)

Automated wound healing assay showing decreased motility of IL-4 treated HCAEC. by Tom Skaria (2733439)

Cardiac overexpression of miR-130a results in decreased FOG-2 expression and a thin ventricular myocardial wall. by Gene H. Kim (371958)

PTH decreased cell apoptosis in a Flt-3L expanded population. by Flavia Q. Pirih (360515)

Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

“…<b>a. RT-qPCR analysis:</b> relative TMPRSS2-ERG fusion variants III and IV mRNA levels were analysed and compared to non-treated cells. …”

Loss of FOXP1 results in decreased number of bRGCs. by Seon Hye E. Park (16765033)

Antitumor Activity of FGFR Inhibitor as a Result of a Decrease in the Breast TIC Subpopulation In Vivo. by Sungeun Kim (105743)

Drugs which cluster on the 'anxiolytic' group decrease 5-HT turnover in the brain. by Caio Maximino (100467)

“…Points represent means and error bars represent standard errors. …”

CD11b and TLR-5 expression are decreased on CF macrophage membrane. by Karin Simonin-Le Jeune (464354)

Eltrombopag markedly decreases levels of ROS in MOLM14 cells. by Anna Kalota (7415)

“…B) Graphic presentation of ROS levels measured by flow cytometry in cells treated with E (5 μM) or DPI (25 μM), an inhibitor of NADPH oxidase known to decrease an intracellular level of ROS, or untreated (CTR) cells. …”

Supplementary Material for: Enhanced Recovery after Surgery for Radical Cystectomy Decreases Postoperative Complications at Different Times by Lannes F. (11465377)

“…There was no significant difference between groups for 90-day readmission (<i>p</i> = 0.349). Mean length of stay did not differ significantly between ERAS and non-ERAS groups (12.7 ± 6.2 and 13.1 ± 5.7 days, respectively; <i>p</i> = 0.743). …”

Targeted point mutation (F639A) in the GluN1 subunit decreases ethanol sensitivity of NMDA receptors. by Carolina R. den Hartog (484817)

Comparison of mean differences in temperature decreases. by Hans-Jörg Gillmann (8460585)

BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”